|Day Low/High||110.50 / 112.43|
|52 Wk Low/High||92.98 / 137.54|
Celgene shares jumped as the biotech company posted top-and bottom-line beats and raised its earnings forecast for the year.
Earnings reports from Celgene and Bristol-Myers show the importance of great science for pharma and biotech companies, according to Jim Cramer.
Trade-Ideas LLC identified Celgene (CELG) as a pre-market leader candidate
Celgene (CELG) stock is trading higher pre-market after reporting its 2016 second quarter financial results.
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,745 million for the second quarter of 2016, a 22 percent increase from the same period in 2015.
TheStreet highlights 3 stocks pushing the health care sector lower today.
When your top line declines, it's harder to convince investors it's okay to wait years see if a partnership in an early-stage biotech company delivers a home-run drug.
Anheuser-Busch increases its offer for SABMiller after Brexit while the Federal Reserve prepares for action against Goldman Sachs.
Celgene will not seek approval for Revlimid as a maintenance therapy for patients with diffuse large B-cell lymphoma based on the lack of a survival benefit in a clinical trial.
Celgene Corporation (NASDAQ: CELG) and the Lymphoma Study Association (LYSA) today announced that the Lymphoma Academic Research Organisation (LYSARC) reported initial data from a phase III, randomized, double-blind,...
Chipotle, Wendy's on the bull side and gold stocks on the bear side.
Cramer is gearing up for the heaviest week of this earnings season, but he's also providing his game plan for helping you be a better investor.
TheStreet’s Chris Versace and Bob Lang said biotech companies like Celgene (CELG) are slowly but surely staging a quiet resurgence.
It denies higher prices to late-to-the-party bulls who need another lift to turn red into green.
Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies.
Trade-Ideas LLC identified Celgene (CELG) as a strong on high relative volume candidate
It's time to unload these toxic stocks from your portfolio.
Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.
GED-0301 is one of three drugs -- Otezla and ozanimod are the others -- which form the core of Celgene's burgeoning immunology and inflammation franchise.
A look at who will be up and who will down this earnings season.
They need to do something that makes them stand out as stocks you want to own, not avoid.
Cramer shares his views on why something could be up in biotech, restaurants and retail. Celgene, Regeneron and Domino's are among the stocks discussed.
Shareholders could be in for a surprise if an upcoming drug for pediatric Crohn's gains FDA approval.
A call with investors Wednesday highlights drugs in the pipeline that could be attractive to bidders that reportedly include Sanofi, Pfizer and Celgene, among others.
A dovish Federal Reserve in June pushes equities, crude to close around session highs.